Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules

At Week 24, 62.2% of 45 participants with available data met the threshold for clinically important improvement in patient-reported impacts.

Rhea-AI Summary

Neurocrine Biosciences (NBIX) reported survey findings showing fewer work and school disruptions among adults with tardive dyskinesia after starting INGREZZA. Reported disruptions fell from 57% to 21%, while average missed work or school days per month declined from 5.6 to 2.0. Employment-related findings used small analysis populations and carry a caution on interpretation.

A separate post-hoc analysis of the KINECT-PRO Phase 4 open-label study, in which participants knew their treatment, assessed patient-reported impacts. Among 45 participants with Week 24 data, 82.2% reported some improvement in total Tardive Dyskinesia Impact Scale scores; 62.2% met the threshold for clinically important improvement. Mean scores improved by 40%–70% across six areas among participants reporting impacts in those areas at baseline. The findings are being presented at the Neuroscience Education Institute Fall Congress.

Positive

• Minor pointINGREZZA survey respondents reported work or school disruptions falling from 57% before treatment to 21% after starting treatment.
• Minor pointAverage missed work or school days declined from 5.6 to 2.0 per month after starting INGREZZA.
• Minor pointWorkplace or school self-consciousness fell from 68% before treatment to 35% after starting INGREZZA.
• Minor pointImproved work or school productivity was reported by 51% of respondents after starting INGREZZA.
• Minor pointWeek 24 TDIS improvement reached 82.2% for any improvement; 62.2% for clinically important improvement among 45 participants with data.

5 minor points

• Minor pointWeek 24 mean TDIS scores decreased 40%–70% across six areas among participants reporting baseline impacts.
• Minor pointBroader survey respondents strongly agreed VMAT2 treatment improved quality of life and daily activities: 94%.
• Minor pointBroader survey respondents strongly agreed VMAT2 treatment improved daily functioning and independence: 93%.
• Minor pointBroader survey respondents strongly agreed VMAT2 treatment improved overall happiness and health: 93%.
• Minor pointBroader survey respondents strongly agreed VMAT2 treatment improved participation in hobbies and interests: 91%.

Negative

• Minor pointEmployment-related survey findings used small analysis populations of fewer than 100 respondents, requiring caution in interpretation.
• Minor pointKINECT-PRO findings came from a post-hoc analysis of an open-label study, with Week 24 data available for 45 participants.

Key Figures

Work or school disruptions: 57% before treatment; 21% after starting treatment Monthly missed work or school days: 5.6 before treatment; 2.0 after starting treatment Any TDIS total-score improvement: 82.2% (≥1-point reduction) +2 more

Work or school disruptions

57% before treatment; 21% after starting treatment

Respondents with TD taking INGREZZA (n=63)

Monthly missed work or school days

5.6 before treatment; 2.0 after starting treatment

Reported average among respondents with TD taking INGREZZA

Any TDIS total-score improvement

82.2% (≥1-point reduction)

KINECT-PRO participants with available Week 24 data (n=45)

TDIS improvement meeting MCID threshold

62.2% (≥4-point reduction)

KINECT-PRO participants with available Week 24 data (n=45)

Mean TDIS area-score decreases

40% to 70%

Across six areas at Week 24 among participants reporting baseline impact

Historical Context

1 past event · Latest: Oct 26

1 event

1. Oct 26

   Patient-reported outcomes

   24h Move

   +2.2%

   Prior KINECT-PRO results showed 13.1-point Week 24 EQ VAS improvement; this update adds TDIS outcomes.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

vesicular monoamine transporter 2 (vmat2) inhibitor, post-hoc analysis, patient-reported outcomes (pros), minimal clinically important difference (mcid), +1 more

5 terms

vesicular monoamine transporter 2 (vmat2) inhibitor medical

"a vesicular monoamine transporter 2 (VMAT2) inhibitor"

A vesicular monoamine transporter 2 (VMAT2) inhibitor is a drug that reduces the storage and release of certain brain chemicals—like dopamine—by blocking the cellular 'pump' that loads them into storage vesicles. For investors, VMAT2 inhibitors matter because they can treat movement and psychiatric disorders, so clinical trial results, safety issues, and regulatory approval directly affect a drug maker’s future revenue and risk profile—think of it as turning down a faucet that controls signaling in the brain.

post-hoc analysis technical

"a post-hoc analysis of KINECT-PRO provided a deeper look"

Post-hoc analysis is an examination of data carried out after an experiment, trial, or reporting period to look for patterns or explanations that were not specified beforehand. It matters to investors because such findings can suggest new opportunities or risks but are more likely to be chance results than preplanned conclusions, so they require independent confirmation before being treated as reliable — like noticing a pattern on a map after a trip and then testing it on the next journey.

patient-reported outcomes (pros) medical

"multiple validated patient-reported outcomes (PROs), including the TDIS"

Patient-reported outcomes (PROs) are direct reports from patients about how a treatment affects their symptoms, daily functioning, or quality of life, without interpretation by clinicians. Think of them as customer reviews for medicines or devices: they show whether a therapy meaningfully improves patients’ lives. For investors, PROs matter because strong, credible patient feedback can influence regulatory approvals, labeling claims, payer reimbursement and market uptake, all of which affect a product’s commercial value.

minimal clinically important difference (mcid) medical

"the minimal clinically important difference (MCID) threshold"

The minimal clinically important difference (MCID) is the smallest change in a clinical outcome measure that patients or clinicians consider meaningful enough to indicate a real improvement (or worsening) in health and that might justify a change in treatment. MCIDs are estimated for a specific measurement tool, patient group, and clinical context using methods such as anchor-based comparisons to patient-reported change or distribution-based statistics; therefore an MCID is not a universal number and can differ by instrument, population, and study design. It is a threshold for practical, patient-centered relevance and is distinct from statistical significance, which only indicates whether an observed change is unlikely to be due to chance.

open-label study medical

"The KINECT-PRO™ Phase 4, open-label study"

An open-label study is a type of research where both the participants and the researchers know which treatment or intervention is being administered. This transparency can influence the results, making it important for investors to consider potential biases or limitations when evaluating the study’s findings. Understanding this helps assess the reliability of evidence supporting new products or therapies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Survey reveals work or school disruptions among adults with tardive dyskinesia declined from 57% before treatment to 21% after starting INGREZZA, with average missed days per month decreasing from 5.6 to 2.0
• A separate post-hoc analysis of KINECT-PRO™ data showed patient-reported improvement with INGREZZA across all six physical and socio-emotional areas assessed by the Tardive Dyskinesia Impact Scale (TDIS™) among participants reporting impacts to those areas at baseline

SAN DIEGO, Nov. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey showing that adults with tardive dyskinesia (TD) reported fewer disruptions to work and school after starting treatment with INGREZZA^® (valbenazine) capsules.¹ A separate post-hoc analysis of the KINECT-PRO™ Phase 4 open-label study showed robust patient-reported improvement with INGREZZA across all six physical and socio-emotional areas measured by the Tardive Dyskinesia Impact Scale (TDIS™) among participants who reported impacts in those areas at baseline. The TDIS is the only psychometrically validated tool that measures the burden of TD from a patient's perspective. The findings will be presented at the Neuroscience Education Institute Fall Congress 2026 taking place Nov. 5-8 in Colorado Springs, Colo.

"Tardive dyskinesia is characterized by involuntary movements, but the patient experience extends beyond movement severity alone," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. "These findings add to an extensive and established body of evidence demonstrating that INGREZZA not only reduces uncontrolled movements but also that patients reported meaningful improvements in their daily functioning and quality of life with treatment."

Survey Findings Show Fewer Work and School Disruptions After Starting INGREZZA:

The quantitative survey was conducted online in the United States by Ipsos on behalf of Neurocrine from Jan. 15 to Feb. 17, 2026. It included 100 individuals: 70 adults diagnosed with TD by a healthcare provider who were receiving or previously received treatment with a vesicular monoamine transporter 2 (VMAT2) inhibitor, including INGREZZA, and 30 nonprofessional care partners.

Building on previously reported findings from the same survey showing the substantial impact of TD on work, school, and productivity prior to treatment, the new analysis provides insights into patient experiences following treatment, including among patients treated with INGREZZA.

Key findings among respondents with TD taking INGREZZA (n=63)*:

• Fewer work and school disruptions: 57% reported disruptions to work or school before treatment, compared with 21% after starting treatment.
• Less self-consciousness: 68% reported feeling self-conscious in a workplace or school setting before treatment, compared with 35% after starting treatment.
• Fewer missed days: The average number of missed days of school and work reported per month decreased from 5.6 before treatment to 2.0 after starting treatment.
• Improved productivity: 51% of respondents reported improvements in productivity at work or school after starting treatment.

Across the broader survey population (n=100), a majority of whom received treatment with INGREZZA, respondents strongly agreed that VMAT2 inhibitor treatment led to improvements in quality of life and daily activities (94%), daily functioning and independence (93%), overall happiness and health (93%), and the ability to participate in hobbies and interests (91%).

KINECT-PRO Analysis Shows Clinically Meaningful Patient-Reported Improvement with INGREZZA:

In a separate Neuroscience Education Institute (NEI) congress presentation, a post-hoc analysis of KINECT-PRO provided a deeper look at patient-reported improvement with INGREZZA. Previous KINECT-PRO findings reported by patients on INGREZZA showed clinically meaningful improvements in TDIS total score, regardless of underlying psychiatric diagnosis or TD movement severity, including among patients with mild movements. The new analysis evaluated the proportion of participants who met stringent and meaningful thresholds for improvement in TDIS total score and examined changes within individual TDIS areas among participants who reported impacts in those respective areas at baseline.

KINECT-PRO is currently the only study to assess the effects of a VMAT2 inhibitor (INGREZZA) on quality of life and functionality using multiple validated patient-reported outcomes (PROs), including the TDIS. The TDIS includes 11 questions assessing six physical and socio-emotional areas: mouth/throat function, dexterity, mobility, emotional, pain, and social.

Key results include:

• Among participants with available data at Week 24 (n=45), 82.2% reported any improvement (≥1-point reduction) in TDIS total score, while 62.2% reported improvement consistent with the minimal clinically important difference (MCID) threshold for TDIS total score improvement (≥4-point reduction).
  • INGREZZA is the only FDA-approved treatment for TD with clinically meaningful improvements in TD impacts using an MCID threshold that is aligned with FDA guidance for PRO reporting.
• Among participants reporting an impact in a given TDIS area at baseline, mean percentage decreases in TDIS scores, indicating improvement, ranged from 40% to 70% across all six areas at Week 24.

*Post-treatment employment-related findings were based on small analysis populations of fewer than 100 respondents with TD who met the study's employment criteria. Exercise caution when interpreting results.

For more information about Neurocrine's research presentations at NEI Fall Congress 2026, read our press release.

Survey Methodology
The research was conducted online in the United States by Ipsos on behalf of Neurocrine Biosciences among 100 individuals, including 70 people who have been diagnosed with tardive dyskinesia (TD) by a healthcare provider and 30 caregivers of people with TD. Of those individuals, 59 met employment criteria, defined as being currently employed (part time or full time), a student, a volunteer, or unemployed but actively looking for work. Caregivers were defined as a partner/spouse or family member who is not a professional caregiver paid by the patient for their services. The 20-minute quantitative online survey was conducted Jan. 15 to Feb. 17, 2026.

About Tardive Dyskinesia
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrolled, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (antipsychotics) that help control dopamine receptors in the brain. Taking antipsychotics commonly prescribed to treat mental illnesses such as major depressive disorder, bipolar disorder, schizophrenia, and schizoaffective disorder and other prescription medicines (metoclopramide and prochlorperazine) used to treat gastrointestinal disorders are associated with TD. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be mild to severe and are often persistent and irreversible. TD is estimated to affect at least 800,000 adults in the U.S.

About the KINECT-PRO™ Phase 4 Study
The KINECT-PRO™ Phase 4, open-label study was designed to evaluate patient-reported outcomes on the use of INGREZZA^® (valbenazine) capsules in a tardive dyskinesia (TD) patient population reflective of real-world clinical practice. Participants had at least mild TD, were aware of and experiencing at least mild distress from their abnormal, involuntary movements and had a clinical diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depression. The KINECT-PRO study included a four-week screening period, a 24-week treatment period during which participants received 40 mg of INGREZZA once-daily for the first four weeks, followed by flexible dosing of 40 mg, 60 mg, or 80 mg once-daily based on individual treatment needs and a two-week safety follow-up period. Baseline socio-demographic and clinical characteristics of the participants were broadly similar to those of the KINECT^® 3 and KINECT^® 4 studies.

KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on TD using multiple clinically validated scales, including the Tardive Dyskinesia Impact Scale (TDIS™). The TDIS is the only patient-reported outcome instrument designed for and psychometrically validated in tardive dyskinesia patients that measures the physical, social, and emotional impact of the involuntary movements of the condition.

About the Tardive Dyskinesia Impact Scale
The Tardive Dyskinesia Impact Scale (TDIS™) is the only patient-reported outcome instrument designed for and validated in tardive dyskinesia patients that measures the physical, social, and emotional impact of the involuntary movements of the condition. It was developed by Neurocrine Biosciences in partnership with thought leaders in neurology and psychiatry from qualitative studies and Phase 3 trials of INGREZZA for the treatment of TD (KINECT^® 3 and KINECT^® 4) as a comprehensive measure of impact and burden of TD from a patient's perspective. The TDIS consists of 11 questions evaluating physical and socio-emotional impact. Six scales are assessed: mouth/throat, dexterity, mobility, pain, social, and emotional. The TDIS allows people with TD to rate how their symptoms affect daily activities and how their uncontrollable movements make them feel. The questionnaire captures relevant information about the impact of TD to provide a more holistic assessment of the condition. Validation of this scale was published in the Journal of Patient-Reported Outcomes.

About INGREZZA® (valbenazine) Capsules and INGREZZA^® SPRINKLE (valbenazine) Capsules
INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD). Only INGREZZA offers a therapeutic dose from day one with no required titration.

INGREZZA, developed by Neurocrine Biosciences, selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic, or muscarinic receptors. While the specific way INGREZZA works to treat TD and HD chorea is not fully understood, INGREZZA is unique in that it selectively and specifically targets VMAT2 to inhibit the release of dopamine, a chemical in the brain that helps control movement. INGREZZA is believed to reduce extra dopamine signaling, which may lead to fewer uncontrollable movements.

INGREZZA is studied across the widest range of patients. It is always one capsule, once daily and can be taken together with most stable mental health regimens such as antipsychotics or antidepressants. Only INGREZZA offers the benefit of a sprinkle formulation, INGREZZA SPRINKLE, for those who experience dysphagia, have difficulty swallowing or prefer not to swallow a pill. INGREZZA and INGREZZA SPRINKLE dosages approved for use are 40 mg, 60 mg, and 80 mg capsules.

Important Information
Approved Uses
INGREZZA^® (valbenazine) capsules or INGREZZA^® SPRINKLE (valbenazine) capsules are prescription medicines used to treat adults with:

• movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).
• involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions.

It is not known if INGREZZA or INGREZZA SPRINKLE is safe and effective in children.

IMPORTANT SAFETY INFORMATION

INGREZZA or INGREZZA SPRINKLE can cause serious side effects in people with Huntington's disease, including: depression, suicidal thoughts, or suicidal actions. Tell your healthcare provider before you start taking INGREZZA or INGREZZA SPRINKLE if you have Huntington's disease and are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is especially important when INGREZZA or INGREZZA SPRINKLE is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of hurting yourself.

Do not take INGREZZA or INGREZZA SPRINKLE if you:

• are allergic to valbenazine, or any of the ingredients in INGREZZA or INGREZZA SPRINKLE.

INGREZZA or INGREZZA SPRINKLE can cause serious side effects, including:

• Allergic reactions. Allergic reactions, including an allergic reaction that causes sudden swelling called angioedema, can happen after taking the first dose or after many doses of INGREZZA or INGREZZA SPRINKLE. Signs and symptoms of allergic reactions and angioedema include: trouble breathing or shortness of breath, swelling of your face, lips, eyelids, tongue, or throat, or other areas of your skin, trouble with swallowing, or rash, including raised, itchy red areas on your skin (hives). Swelling in the throat can be life-threatening and can lead to death. Stop taking INGREZZA or INGREZZA SPRINKLE and go to the nearest emergency room right away if you develop these signs and symptoms of allergic reactions and angioedema.
   
• Sleepiness and tiredness that could cause slow reaction times (somnolence and sedation). Do not drive a car or operate dangerous machinery until you know how INGREZZA or INGREZZA SPRINKLE affects you. Drinking alcohol and taking other medicines may also cause sleepiness during treatment with INGREZZA or INGREZZA SPRINKLE.
   
• Heart rhythm problems (QT prolongation). INGREZZA or INGREZZA SPRINKLE may cause a heart rhythm problem known as QT prolongation. You have a higher chance of getting QT prolongation if you also take certain other medicines during treatment with INGREZZA or INGREZZA SPRINKLE. Tell your healthcare provider right away if you develop any signs or symptoms of QT prolongation, including: fast, slow, or irregular heartbeat (heart palpitations), shortness of breath, dizziness or lightheadedness, or fainting or feeling like you are going to faint.
   
• Neuroleptic Malignant Syndrome (NMS). NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms and they do not have another obvious cause: high fever, stiff muscles, problems thinking, irregular pulse or blood pressure, increased sweating, or very fast or uneven heartbeat.
   
• Parkinson-like symptoms. Symptoms include: body stiffness, drooling, trouble moving or walking, trouble keeping your balance, shaking (tremors), or falls.

Before taking INGREZZA or INGREZZA SPRINKLE, tell your healthcare provider about all of your medical conditions including if you: have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Make sure you tell all of your healthcare providers that you are taking INGREZZA or INGREZZA SPRINKLE. Taking INGREZZA or INGREZZA SPRINKLE with certain other medicines may cause serious side effects. Especially tell your healthcare provider if you: take digoxin or take or have taken a monoamine oxidase inhibitor (MAOI) medicine. You should not take INGREZZA or INGREZZA SPRINKLE if you are taking, or have stopped taking, a MAOI within the last 14 days.

The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with tardive dyskinesia are sleepiness and tiredness.

The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with chorea associated with Huntington's disease include sleepiness and tiredness, raised itchy red areas on your skin (hives), rash, and trouble getting to sleep or staying asleep.

These are not all of the possible side effects of INGREZZA or INGREZZA SPRINKLE. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dosage Forms and Strengths: INGREZZA and INGREZZA SPRINKLE are available in 40 mg, 60 mg, and 80 mg capsules.

Please see full Prescribing Information including Boxed Warning, and Medication Guide.

About Neurocrine Biosciences, Inc. 
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis*, and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook, and YouTube. (*in collaboration with AbbVie)  

The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, KINECT, and INGREZZA are registered trademarks of Neurocrine Biosciences, Inc. KINECT-PRO and TDIS are trademarks of Neurocrine Biosciences, Inc.

Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from INGREZZA, the interpretation and potential relevance of the data described in this press release, including statements regarding reported reductions in work or school disruptions after starting INGREZZA and patient-reported improvements across physical and socio-emotional areas assessed by the Tardive Dyskinesia Impact Scale (TDIS), and the value INGREZZA may bring to patients. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties as to whether the data described in this press release will be replicated in additional studies or will be predictive of efficacy or other clinical outcomes in subsequent clinical studies or real-world use of INGREZZA; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of INGREZZA; whether INGREZZA receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for INGREZZA; risks associated with the Company's dependence on third parties for development and manufacturing activities related to INGREZZA, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for INGREZZA or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding INGREZZA; risks that post-approval INGREZZA commitments or requirements may be delayed; risks that INGREZZA may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions, or incidents of misuse; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2026. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.

REFERENCES

1. Ipsos (2026). Tardive Dyskinesia Claims Research Report [Unpublished survey]. Ipsos.

© 2026 Neurocrine Biosciences, Inc. All Rights Reserved. CAP-VBZ-US-0111   11/2026 

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-tardive-dyskinesia-survey-results-showing-fewer-work-and-school-disruptions-with-ingrezza-valbenazine-capsules-302930000.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Neurocrine's INGREZZA survey show about work and school disruptions?

Reported work or school disruptions declined from 57% before treatment to 21% after starting INGREZZA. Average missed days per month decreased from 5.6 to 2.0. The employment-related findings were based on small analysis populations and should be interpreted cautiously.

What did Neurocrine's KINECT-PRO analysis show at Week 24?

Among 45 participants with available Week 24 data, 82.2% reported at least a 1-point reduction in total Tardive Dyskinesia Impact Scale score, and 62.2% met the clinically important improvement threshold of at least a 4-point reduction. Lower scores indicate improvement.

How was Neurocrine's tardive dyskinesia survey conducted?

Ipsos conducted a 20-minute online U.S. survey from Jan. 15 to Feb. 17, 2026, on Neurocrine's behalf. It included 70 adults diagnosed with tardive dyskinesia who currently or previously received a VMAT2 inhibitor and 30 nonprofessional care partners. Across the survey, 59 individuals met employment criteria, which included students, volunteers and people actively seeking work.